Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
  • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
  • A61P25/16—Anti-Parkinson drugs
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/22—Anxiolytics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/24—Antidepressants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
  • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
  • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
  • C07D243/12—1,5-Benzodiazepines; Hydrogenated 1,5-benzodiazepines
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
  • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
  • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
  • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
  • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
  • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
  • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
  • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
  • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
  • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
  • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
  • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
  • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
  • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
  • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
  • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

• Proglumide is already known as a gastrin receptor antagonist as a treatment for gastric ulcer and gastritis.
• proglumide has a rather low affinity for gastrin or CCK-B receptor, and its therapeutic effect is also weak.
• L-364, 718 Divazepid, JP-A-61-63666
• L-365, 260 JP-A-63-23880
• n an integer of 0 to 2]
• the present invention provides the use of the compound (I) as a medicament.
• the present invention relates to a gastrin receptor and / or cholecystokinin (CCK) -B receptor, which comprises administering an effective amount of the compound (I) to a mammal including human. It provides a method for preventing and treating diseases.
• CCK cholecystokinin
• lower alkyl includes, for example, methyl, ethyl, propyl, isopropyl, cyclopropyl, butyl, isopropyl, sec-butyl, tert-butyl, cyclobutyl, cyclopropylmethyl Group, 1-methylcyclopropyl, 2-methylcyclopropyl, pentyl, 1-methylbutyl, 2-methylbutyl, isopentyl, tert-pentyl, 1,2-dimethylpropyl, neopentyl , 1-ethylpropyl, cyclopentyl, 1-methylcyclobutyl, 2-methylcyclobutyl, 3-methylcyclobutyl, cyclobutylmethyl, 1-cyclopropylethyl, 2-cyclopropylethyl Group, (1-methylcyclopropyl) methyl group, (2-methylpropyl pill) Butyl, hexyl, 1-methylpentyl, 2-methyl
• the “lower alkenyl group” includes vinyl, 1-propenyl, aryl, isopropyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-methyl-1 Propenyl, 2-methyl-1-propenyl, 1-methyl-2-propenyl, 2-methyl-2-propenyl, 1-pentenyl, 2-pentenyl, 3 —Pentenyl group, 4-pentenyl group, 1—ethyl-1—propenyl group, 1,2—dimethyl-1-propenyl group, 1-ethyl-2—propenyl group, and 2-dimethyl-2-pro- Benzyl group, 1-methyl-1-butenyl group, 2-methyl-1-butenyl group, 3-methyl-1-butenyl group, 1-methyl-2-butenyl group, 2-methyl-2-butenyl group, 3-methyl- 2 —butenyl group, 1 —methyl— 3-butenyl group, 2 —Methyl-3-buten
• Carboxyalkylsulfinyl group means a group in which the above “carboxyalkyl group” is bonded to a sulfinyl group, and “lower-alkyloxycarbonylsulfonyl group” means “carboxyalkylsulfinyl group” Means a group obtained by substituting 1H of the carboxyl group of the above with the above-mentioned lower alkoxy group.
• alkoxycarbonyl group examples include a group formed by bonding the above “lower alkoxy group” to a carbonyl group.
• R 5 includes, among these —Y—C ⁇ R, a carboxyl group, a 3- hydroxycarbonyl group, a benzyloxycarbonyl group, a carboxyalkyl group, an 8- alkoxycarbonyl C- 8 alkyl group, a benzyl group Okishikarubo two Le Ji ⁇ alkyl group, a carboxy C, - 8 alkylthio group, C i - 3 Arukokishikaru Poniru C i - 8 alkylthio group, more preferably benzyl O alkoxycarbonyl C i 8 alkylthio group, a carboxy group or Karubokin A methylthio group is particularly preferred.
• Organic salts such as (R) or (S) -form phenethylamine, benzylamine, and 4-methylbenzylamine salt.
• the present invention also includes the compound (I) of the present invention, various solvates such as hydrates of the compound, and polymorphic substances. Furthermore, the racemic form of the compound (I) of the present invention, All stereoisomers, diastereomeric mixtures, and optical isomers are also included.
• the compound (I) of the present invention can be produced by applying various synthetic methods in consideration of the characteristics of its basic skeleton and groups, and typical production methods are shown below. Manufacturing method A
• the solvent used may be any solvent that does not affect the reaction, and is usually 1,2-dichloro-c / ethane, salt Halogen-based solvents are used methylene etc.
• R 3 is a lower alkyl group, when a lower A ⁇ Ke alkylsulfonyl group or a group one CHR S R 7 are methanol, and alcohol solvents such as ethanol, N, Polar solvents such as N-dimethylformamide and dimethylsulfoxide can also be used.
• the reaction can be performed at a temperature ranging from 0 ° C to the reflux temperature.
• an isocyanato compound (R 3 —NCO) can be used as the compound (ffi). In this case, a compound having an amide bond at the 5-position of the benzodiazepine ring is obtained.
• the 1,5-substituted (VI) is obtained by reacting the compound (V) with the monosubstituted (IV).
• the reaction is usually carried out by adding a base such as sodium hydride, sodium hydroxide or potassium carbonate to the 5-substituted compound (IV), adding (V) and, if necessary, adding an aqueous phase such as tetrabutylammonium bromide. This is performed by adding a transfer catalyst.
• the solvent used in the reaction may be any solvent that does not affect the reaction. Usually, ether solvents such as tetrahydrofuran and dioxane, toluene, N, N-dimethylformamide, dimethyl sulfoxide and the like are used.
• reaction can be performed in a two-phase system such as a water-toluene system using a phase transfer catalyst such as tetrabutylammonium.
• phase transfer catalyst such as tetrabutylammonium.
• the reaction can be carried out in the range of 0 to 150 ° C.
• This step can also be performed after performing the operations of Step A1, Step A3 and Step A4.
• the compound (I) of the present invention can be obtained by reacting the compound (VIII) with the amine (VII).
• the solvent used in the reaction may be any solvent that does not affect the reaction, and is usually an ether solvent such as tetrahydrofuran or the like, toluene, benzene or the like. Hydrocarbon solvents, methylene chloride, 1,2-dichloroethane, halogen solvents such as chloroform, and polar solvents such as ⁇ , ⁇ -dimethylformamide and acetonitrile can be used.
• the reaction is usually performed in the range of 0 ° C to reflux temperature.
• the solvent used in the reaction may be any solvent that does not affect the reaction, and is usually an ether solvent such as tetrahydrofuran or dioxane, a halogen solvent such as methylene chloride, or a hydrocarbon solvent such as toluene or benzene.
• a solvent is used.
• the reaction is usually carried out at a temperature in the range of 0 ° C to the reflux temperature, and in the case of the Curtius rearrangement reaction, it is preferable to carry out the reaction at a temperature in the range of 50 ° C to the reflux temperature. Manufacturing method B
• Step B 1 (Wherein, A, B, G,, R 3 , R 4 , R 5 and Ar have the same meanings as described above)
• R 3 "an optionally substituted phenyl group" is obtained by producing the compound OVa) by the following method, and then, in the step A2 of the production method A, (IV) In place of (IVa) instead of (IVa) and then performing the operations of steps A3 and A4, or in step B1 of process B, using (IVa) instead of (II) It can be produced by performing the operations of Steps B3 and B4. NO,
• Compound (I) of the present invention is obtained by reacting compound ( ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ) with monoamine (XVI). The reaction is usually performed in the same manner as in Step A1.
• m represents a number of 1 to 4, and E represents the same as described above.
• the compound (I) of the present invention further undergoes hydrolysis, solvolysis, hydrogenolysis or hydrogenation. This can lead to another compound (I) of the present invention.
• R 4 or R 5 is a group having a carboxy group
• a condensing agent such as methylene chloride
• various reagents such as tetronic acid, thiotetronic acid, primary or secondary amines, amino acid esters and alcohols. can do.
• the thus-produced compound (I) of the present invention is isolated or purified as free or as a salt.
• a liquid preparation for injection can be prepared by combining with water, ethanol, glycerin and the like.
• the dose of the compound (I) of the present invention or a salt thereof required for the therapeutic or prophylactic effect of the above-mentioned diseases varies depending on its formulation, administration form, age and symptoms, but the daily oral dose for an adult is usually It is 1 to 100 Omg, preferably 5 to 50 Omg.
• As an administration method it is preferable to administer the drug in two or three times a day.
• 2-Amino-3-benzene prepared in accordance with a known method (C. hem. Pharm. Bull., Vol. 7, 616 (1959)) was prepared by adding 2.05 g of sodium carbonate to an aqueous solution of 100 ⁇ . Child power 4.6 g of luponylaminopropionic acid was added, and then a solution of 4.68 g of di-tert-butyl dicarbonate in 100 parts of tetrahydrofuran was added, followed by stirring at room temperature overnight. The reaction solution was washed with ethyl acetate, adjusted to pH 3 by adding 1N hydrochloric acid to the aqueous layer, and extracted with methylene chloride. The organic layer was dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure to obtain 6.51 g of the title compound.
• N- (2-Ditrophenyl) -N- (2-cyanoethyl) aniline 47 To a suspension of 7.1 g of ethanol 500 was added 4.7 g of 10% palladium on carbon, and the mixture was stirred under a hydrogen atmosphere. The mixture was stirred at normal pressure and room temperature for 1 hour and 30 minutes. The reaction solution was filtered, the filtrate was concentrated under reduced pressure, and the residue was dissolved in ethanol 400. To this was added 79.1 g of an aqueous solution of potassium hydroxide (700), and the mixture was heated under reflux for 4 hours.
• potassium hydroxide 700
• Examples 1 to 176 show production examples of the compound (I) of the present invention.
• step 4 of Example 1 (2-toluoylmethyl) -2-oxo-1-3-amino-5-bivaloylu 1,3,4,5-tetrahydro-1H instead of 1,5-benzodiazepine
• (2-toluoylmethicide) 2-oxo-1-3-amino-5-bivaloyl-8-methyl-1,3,4,5-tetrahydro 2H—1,5Similar using benzodiazepine
• the operation was performed to obtain the title compound.
• Step 2 of Example 1 2-oxo-l-tert-butoxycarbonylamino 5- 5-bivaloylu 1,3,4,5-tetrahydro 2H-l, 5-benzodiazepine was replaced with 2-oxo2
• the same procedure was carried out using 3-tert-butoxycarbonylamino-5-pivaloyl-1-8-fluoro-1,3,4,5-tetrahydro 2H-1,5-benzodiazepine to obtain the title compound. .
• Step 3 of Example 1 1- (2-toluoylmethyl) -12-oxo-3-1-tert-butoxycarbonylamino-5-bivaloylu 1,3,4,5-tetrahydro-2H- 1,5
• 1 (2-toluoylmethyl) 1- 2-kiofu 3- 3-tert-butoxycarbonylamino-5-bivaloylu 8 8-fluoro-1,3,4,5-tetrahydrau 2H-1 The same operation was performed using 5-benzodiazepine, and then the operation was performed in the same manner as in Step 4 of Example 1 to obtain the title compound.
• Step 3 of Example 1 1- (2-toluoylmethyl) -12-oxo-3-1-tert-butoxycarponylamino-5-bivaloyl-1, 3,4,5-tetrahydro 2H-1 1-isobutyl-2-oxo-l-tert-butoxycarbonylamino-5-bivaloyl-l, 3,4,5-tetrahydro-2H-l, 5-benzodiazepine instead of 1,5-benzodiazepine The same operation was performed, and then the operation was performed in accordance with the procedure 4 of Example 1 to obtain the title compound.
• Step 3 of Example 1 1- (2-toluoylmethyl) -2-oxo-l-tert-butoxycarbonyl-l-amino-5-bivaloyl-l, 3,4,5-tetrahydro 2H- i, 5
• 1-benzodiazepine 1-cyclopropylcarbonylmethyl-2-oxo-3-tert-butynecarbonylamino 1-5, bivaloyl 1,3,4,5-tetrahydro-2H—
• the same operation was performed using 5-benzodiazepine, and then the operation was performed according to the procedure 4 of Example 1 to obtain the title compound. Melting point: 184-186 ° C
• Step 1 of Example 1 the same operation was performed using methoxyacetyl chloride instead of bivaloyl chloride to obtain the title compound.
• Step 3 of Example 1 1- (2-toluoi meth) —2-oxo 3 —tert-butoxycarbonylamino 1 5 pivaloylu 1,3,4,5—tetrahydro 2 H—1,5 1- (2—toluoylmethyl) 1 2—oxo-1 3 tert-butoxycarbonylamino 5—methoximethy carboneru 1,3,4,5—tetrahydro-1 2H—1 instead of 1-benzodiazepine The same operation was performed using, 5-benzodiazepine, and then the operation was performed in the same manner as in step 4 of Example 1 to obtain the title compound.
• step 2 of Example 1 2-oxo-3-tert-butoxycarboni amino 5-hydroxyvaluyl 1,3,4,5-tetrahydro-1 2H-1,5 instead of benzodiazepine
• 2-oxo-3- (tert-butoxycarbonylamino) -5-cyclopropylcarbonyl-1,2,3,4,5-tetrahydro 2H-1, 5-benzodiazepine The title compound was obtained.
• Step 2 of Example 1 the same operation was carried out using brothmethyl-tert-butyl ketone instead of 2-promo 2′-methylacetophenone to obtain the title compound.
• reaction solution was concentrated under reduced pressure, water was added to the residue, and the mixture was extracted with methylene chloride.
• Step 3 of Example 1 1- (2-toluoylmethyl) -2-oxo- 1-tert-butoxycarbonylamino-5-bivaloylu 1,3,4,5-tetrahydro- 1 2H-1, Instead of 5-benzodiazepine 1- (2-toluoy methyl) 1-2-oxo-3- 3-tert-butoxycarbonylamino 5- (4-chlorophenyl) carbone 1,3,4,5-
• the same operation was performed using tetrahydro- 1 2 H-1,5-benzodiazepine, and then the operation was performed according to the procedure 4 of Example 1 to obtain the title compound.
• Step 1 of Example 1 the same operation was performed using acetyl chloride instead of bivaloyl chloride to obtain the title compound.
• step 3 of Example i0 1-tert-butylcarbonylmethyl-2-oxo-3-amino-5-bivaloylu 1,3,4,5-tetrahydro 2H-1,5-benzodiazepine
• 1- (2-butane oil meth) obtained in step 3 of Example 4 1-2-oxo-1 3-amino-5-bivaloy-one 8-meth-one-1,3,4
• the same procedure was carried out using 5-tetrahydro 2H-1,5-benzodiazepine.
• the title compound was obtained.
• This salt was suspended in a saturated aqueous solution of sodium bicarbonate and extracted with black-mouthed form. The organic layer was washed with saturated saline, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure to give (-) 1-1 (2-toluoylmethyl) 1-2-oxo 1-3-amino 5 —Vivaloylu-8—methyl-1,3,4,5-tetrahydro-1 2H—1,5—benzodiazepine was obtained. Optical purity 99% ee (Liquid chromatography).
• a solution prepared by dissolving 2.18 g of tetrahydro-1-H, 1,5-benzodiazepine in anhydrous 1,4-dioxane 1 was added dropwise, and the mixture was stirred at room temperature for 1 hour.
• the reaction solution was concentrated under reduced pressure, saturated aqueous sodium hydrogen carbonate was added to the residue, and the mixture was extracted with chloroform. The organic layer was washed with saturated saline and dried over anhydrous sodium sulfate.
• Step 4 (+) — 1 — (2-toluoylmethyl) 1-2 — oxo 1 3 — amino 5 — Vivaloylu 8 — methyl-1 1, 3, 4, 5 — tetrahydro 2H — 1, 5 — Instead of benzodiazepine (-) 1 1 1 (2—toluoylmethyl) —2—oxo 1—3—amino 1—5—bivaloyl—8—methyl—1,3,4,5—tetrahydro-2H — The same procedure was performed using 1,5-benzodiazepine to obtain the title compound.
• Step 3 of Example 1 1- (2-toluoylmethyl) -2-oxo-3 -tert-butoxycarbonylamino 5-5-pivaloylu 1,3,4,5-tetrahydro 2H-1, 1- (2-toluoylmethyl) 1- 2-oxo- 1- 3-tert-butoxycarbonylamino 5- 5-cyclohexyl carboxylate instead of 5-benzodiazepine 3-, 4-, 5-tetrahydro 2H
• the same operation was carried out using —1,5-benzodiazepine, and then the operation was carried out according to Step 4 of Example 1 to obtain the title compound. Melting point: 148-15C
• Step 3 of Example 15 1- (N-phenyl-N-methyl) -l-bamoylmethyl-2-oxo-l-amino-1 5-phenyl-1, 3,4,5-tetrahydro-2 1-tert-butoxycarbonyl instead of H-1,5-benzodiazepine
• the same operation was carried out using l-methyl-2-oxo-1-amino-5-phenyl-1,3,4,5-tetrahydro 2 ⁇ -1,5-benzodiazepine to obtain the title compound.
• Example 15 In Step 3 of 5, 1- (N-phenyl N-methyl) carbamoylmethyl 1-2-oxo-13-amino-5-phenyl 1,3,4,5-tetrahydro 1 — (2,2,2-tritrifluoro ⁇ ) instead of 1 2 H—1,5—benzodiazepine 1- (2,2,2-trifluo ⁇ ) ethyl-1—oxo-1 3-amino 1 5-feneru 1,3,4,5 —Tetrahydrau 2H—5—Benzodiazepine was used for the same procedure to obtain the title compound.
• step 2 of Example 17 1- (2,2,2-trifluoro) ethyl-2-oxo-3-3-benzyloxycarbonylamino-5-phenyl-1,3,4,5-tetrahydrofuran 1- (2-tonoylmethyl) instead of 2H—1,5—benzodiazepine 1—2-oxofu-3-benzyloquincarbonylamine 5-phenyl-1,3,4,5- The same operation was carried out using tetrahydro-2-H-1,5-benzodiazepine to obtain the title compound.
• Step 3 of Example 15 1- (N-phenyl-N-methyl) -l-bamoy-methyl-2-oxo-1-3-amino-5-phenyl and 3,4,5-tetrahydro 2H — 1,5—Instead of benzodiazepine 1— (2-Toluoylmethyl) 1—2—oxo—3—Amino—5—Feniru 1,3,4,5—Tetrahydro 2H The same operation was performed using 1,5-benzodiazepine to obtain the title compound. Melting point: 210-220 ° C
• step 3 of Example 15 5— (N-phenyl N-methyl) -l-bamoylmethyl-1-oxo-2-3-amino-5-phenyl-1,3-, 4-, 5-tetrahydro-2H—
• 5-benzodiazepine 1-methoxymethyl-2-oxo-2-3-amino-5-phenyl-1,3,4,5-tetrahydro 2H-1,5- obtained in step 7 of Reference Example 3
• the same operation was performed using benzodiazepine to obtain the title compound.
• step 3 of Example 1 (2-toluoylmethyl) —2-oxo—3—tert-butynecarbonylamino-5-bivaloyl—1,3,4,5-tetrahydro-2H— 5 2- (oxo-1-3-tert-butoxycarbonylamino) 5- (4-methylbiperazine-1-yl) methylcarbonyl-1,3-, 4-, 5-tetrahydro-2H instead of 1-benzodiazepine The same operation was performed using —1,5-benzodiazepine, and then the same operation as in step 4 of Example 1 was performed to obtain the title compound.
• step 2 of Example 1 2-oxo-3-tert-butoxycarboniamino-5-bivaloyl-1,3,4,5-tetrahydro-1H-2,5-benzodiazepine
• 2-oxo_3-tert-butoxycarbonylamino 5- (4-methylbiperazine-11-yl) methylcarbonyl obtained in Step 2 of Example 20 methylcarbonyl-1,1,4,4
• the same procedure was performed using 5-tetrahydro-2H-1,5-benzodiazepine to obtain the title compound.
• Step 2 of Example 1 2-oxo-3-tert-butoxycarbonyl-1-amino-5-bivaloyl-1,3,4,5-tetrahydro 2H- and 5-benzodiazepine are replaced with 2-oxo- The same operation was carried out using 3-tert-butoxycarbonylamino-5-benzoyl-1,1,3,4,5-tetrahydro-2H-1,5-benzodiazepine to obtain the title compound. -
• Step 3 of Example 1 1- (2-toluoylmethyl) -2-oxo2-3-tert-butoxycarbonylamino-5-bivaloyl-1-1,3,4,5-tetrahydro-1H-2, 1- (2-toluoylmethyl) -1-2-oxo-1-3-tert-butoxycarbonylamino-5-benzoyl-1,3,4,5-tetrahydro 2H—1,5—instead of 5-benzodiazepine The same operation was performed using benzodiazepine, and then the operation was performed in the same manner as in Step 4 of Example 1 to obtain the title compound.
• Step 2 of Example 10 1-tert-butylcarbonylmethyl-2-oxo-3-tert-butoxycarbonylamino-5-bivaloylue 1,3,4,5-tetrahydro-2H 5
• 1-1 (2-toluoylmethyl) —2-oxo-1 3-tert-butynecarbo obtained in step 2 of Example 22
• the same procedure was carried out using 5-benzoyl-1,5-, 3-tetrahydro-2 ⁇ -1,5-benzodiazepine to obtain the title compound.
• Step 3 of Example 15 1- ( ⁇ -phenyl- ⁇ -methyl) -potamoylmethyl-1-oxo-3-3-amino-5-phenyl-1,3-, 4-, 5-tetrahydro 2- 2 1,5—Instead of benzodiazepine, 1— (2—toluoylmethyl: —2-oxo-1-3-amino-1-5-benzoyl-1,3,4,5-tetrahydro 2 2-1,5— The same operation was performed using nzodiazepine to obtain the title compound. :
• step 2 of Example 1 2-oxo-3-tert-butoxycarbonylamino 5-5-bivaloyl-1,3,4,5-tetrahydro 2H-1,5-benzodiazepine was replaced with 2-oxo. The same operation was carried out using 1-tert-butoxycarbonylamino-5-benzyl-1,3,4,5-tetrahydro-1H-1,5-benzodiazepine to obtain the title compound.
• step 3 of Example 1 1- (2-toluoylmethyl) -2-oxo-13-tert-butoxycarbonylamino-5-bivaloyl-1,3,4,5-tetrahydro 2H-1, 5--benzodiazepine instead of 1- (2-toluoylmethyl )-2-oxo-l3-tert-butoxycarbonylamino-5-benzyl-, 3,4,5-tetrahydro-2H- and 5-benzodiazepine, followed by the same procedure.
• the title compound was obtained in the same manner as in Step 4 of Example 1.
• step 2 of Example 10 1-tert-butylcarbonylmethyl-2-oxo-1-tert-butoxycarbonylamino-5-bivaloyl-1,3,4,5-tetrahydro-2H-1, 1- (2-toluoylmethyl) —2-oxo2 3-tert-butoxycarbonylamino-1 5-benzyl-1 1,3,4,5-tetrahi obtained in Step 2 of Example 24 in place of 5-benzodiazepine The same operation was carried out using draw 2H-1,5-benzodiazepine to obtain the title compound.
• Step 2 of Example 1 2-oxo-3—tert-butoxycarbonylamino 5 —bivaloyl—2,3,4,5-tetrahydro-1 2H—1,2—in place of benzodiazepine
• the same operation was carried out using oxo-3-tert-butoxycarbonylamino 5-(N-cyclohexylcarbamoyl) 1, 1, 3, 4, 5-tetrahydro 2H-1, 5-benzodiazepine.
• the title compound was obtained.
• Step 3 of Example 1 1- (2-toluoylmethyl) -2-oxo-13-tert-butoxycarbonylamino-5-pivaloyl-1,3,4,5-tetrahydro 2H-1, 1- (2-Toluoylmethyl) _2-oxo-l3-tert-butoxycarbonylamino-5- (N-cyclohexylcarbamoyl) -l, 1,3,4,5-tetrahydric port in place of 5-benzodiazepine The same operation was performed using 1 2 H-1,5-benzodiazepine, and then the operation was performed according to the procedure 4 of Example 1 to obtain the title compound. '
• step 2 of Example 1 2-oxo-3-tert-butoxycarboni-amino-5-bivaloylu 1,3,4,5-tetrahydro-1H- 1,5'-benzodiazepine Using 2-oxo-3-tert-butoxycarbonylamino 5- (N, N-dimethyl) -rubamoyl i, 3,4,5-tetrahydro-2-H- and 5-benzodiazepine The same operation was performed to obtain the title compound. 'H-NMRCCDC ⁇ 3 (5:
• Step 2 of Example 1 2-oxo-3-tert-butoxycarbonylamino-5-bivaloyl-1,3,4,5-tetrahydro-1-H, 1,5-benzodiazepine
• 2-oxo-1,3-tert-butoxycarbonylamino-5-cyclopentylcarbonyl-1,1,3,4,5-tetrahydro 2H-1,5-benzodiazepine The same procedure was carried out using 2-oxo-1,3-tert-butoxycarbonylamino-5-cyclopentylcarbonyl-1,1,3,4,5-tetrahydro 2H-1,5-benzodiazepine to give the title compound. Obtained.
• Step 3 of Example 1 1- (2-toluoylmethyl) -12-oxo-2-3-tert-butoxycarbonylamino-5-bivaloyl-1-1,3,4,5-tetra 1- (2-Toluoylmethyl) -1-2-oxo-3- 3-tert-butoxycarbonylamino 5-H-cyclopentylcarbonyl-1,3-, 2-hydroxy-1,3-benzodiazepine The same operation was performed using 4,5-tetrahydro 2H-5-benzodiazepine, and then the same operation as in step 4 of Example 1 was performed to obtain the title compound.
• step 1 of Example 1 the same operation was performed using isobutyryl chloride instead of bivaloyl chloride to obtain the title compound.
• Step 2 of Example 1 2-oxo-3- (tert-butoxycarbonyl) amino-5-bivaloylue 3,4,5-tetrahydro 2H-1 and 5-benzodiazepine instead of 2H-1 and 5-benzodiazepine
• the same procedure was carried out using oxo-2-3-tert-butoxycarbonylamino-5-isobutyryl-1,1,3,4,5-tetrahydro-1H-1,5-benzodiazepine to obtain the title compound.
• step 2 of Example 1 2-bromo- [2-phenyl]-[2-phenyl]-[2- (2-benzyloxyshethyl)] a
• the same operation was performed using acetamide to obtain the title compound.
• Step 2 of Example 10 1-tert-butylca-bonylmethyl-2-oxo-3--3-tert-butoxycarbonyl-amino-5-bivaloylue 1,3,4,5-tetrahydrid c3-2H-1, 1- [ ⁇ -Phenyl- ⁇ - (2-benzyloxyshethyl) -l-rubamoylmethyl] -1-2-oxo-1 3-tert-butynecarbonylamino 5-5-bivaloyl 1-, 5-benzodiazepine The same operation was performed using 3,4,5-tetrahydro 2H-1,5-benzodiazepine, and then the same operation as in step 3 of Example 10 was performed to obtain the title compound.
• 'H-NMRCCDC ⁇ 3 d
• Step 2 of Example 1 the same operation was performed using 2-bromo-N- (1-benzylpiperidin-14-yl) acetamide instead of 2-bromo-2'-methylacetophenone. This gave the title compound.
• Step 2 of Example 10 1-tert-butylcarbonylmethyl-2-oxo-3-tert-butoxycarbonylamino-5-bivaloylu 1,3,4,5-tetrahydro 2H-1,5-
• the same operation was carried out using tetrahydro 2H—1,5—benzodiazepine, and 1— [N— (1-methylpyperidine-14-yl) -powerbamoylmethyl] 1-2-oxo-1-3-amino-1-5— Bivaloylue 1,3,4,5-tetrahydro 2H-1,5-benzodiazepine was obtained.
• Step 3 of Example 1 1- (2-toluoi-methyl) -2-oxo-3-tert-butoxycarbonylamino-5-bivaloyl-1-1,3,4,5-tetrahydro 2H-1, 5 Instead of 1-benzodiazepine, 1-tert-butylcarbonylmethyl-2-oxo-3-tert-butoxycarbonylamino-5-bivaloyl 1,3,4,5—tetrahydro 2H—and 5—benzodiazepine Using the same procedure as above, and then according to Step 4 of Example 1, the title compound was obtained. Melting point: 252-255 ° C (decomposition)
• Example 3 (1-tert-butyl) -carbonyl-methyl-2-oxo-5-phenyl-1,3,4,5-tetrahydro-2H-1,5-benzodiazepine obtained in step 2 of 3 3-yl) 1- 3- (3-ethoxyquincarbonylmethylthiophenyl) ⁇ Dissolve 46 mg of rare earth in 2 methylene chloride and add 17 mg of peroxybenzoic acid under ice-cooling and add 30 mg of peroxybenzoic acid. Stirred for minutes. The reaction solution was purified with saturated aqueous sodium bicarbonate and saturated saline sequentially. After drying over anhydrous sodium sulfate, silica gel column chromatography
• Step 3 of Example 33 1- (1-tert-butylcarbonylmethyl-2-oxo-1-5-phenyl-1,3,4,5-tetrahydro 2H-1,5-benzodiylzepin-13- ) — 3— (3-Ethoxycarbonylmethylthiophenyl) ⁇
• 1- (1-tert-butylcarbonylmethyl-2-oxo-5-phenyl-1, 3,4,5-tetrahydro2 The same procedure was carried out using H-1,5-benzodiazepine-3-yl) -3- (3-ethoxyquincarbonylmethylsulfinylphenyl) urea to obtain the title compound.
• Example 33 In step 2 of 3, a similar procedure was carried out using 3-aminophenoxyacetate in place of 3-aminophenylthioacetate to obtain the title compound.
• Example 3 In step 3 of 3, 1- (1-tert-butylcarbonylmethyl-2-oxo-5-phenyl-1,3,4,5-tetrahydro 2H—1,5—benzodiazepine-1— 1) 3- (3-ethoxycarbonylmethylthiophenyl) ⁇ -lea 1- (1-tert-butylcarbonylmethyl-2-oxo-5-phenyl-1,3,4,5-tetrahydro The same operation was carried out using 2H-1,5-benzodiazepine-13-yl) 13- (3-ethoxycarbonylmethoxyphenyl) to obtain the title compound. '
• Example 3 1-tert-Butylcarbonylmethyl-2-oxo-3, amino-5-phenyl-1,1,3,4,5-tetrahydro 2H-1,5-benzodiazepine obtained in step 1 of 3 35
• To a solution of Omg in 1 Om of methylene chloride was added 209 mg of 3- (N-tert-butynecarbonyl-N-methylamino) phenylisocyanate under ice-cooling, followed by stirring at room temperature for 30 minutes.
• the reaction mixture was concentrated under reduced pressure, and recrystallized from a mixed solvent of n-hexane and ethyl acetate to give 1- (1-tert-butylcarbonylmethyl-2-oxo-1-5-phenyl-1-1,3,4,5).
• —Tetrahydro-1H-2,1,5-benzodiazepine-3-yl) —3— (3-N—tert-butoxycarbonyl—N-methylaminoaminophenyl) ure
• Example 3 7 3-[3-[1-(2-toluoylmethyl) 1-2-oxo-1-pivaloy-1, 3, 4, 5-tetrahydro-1 2 H-1, 5-benzodiazepine-1-3-yl ] ⁇ Raid]
• step 2 of Example 10 1-tert-butylcarbonylmethyl-2-oxo-1-3-tert-butoxycarbonylamino-5-bivaloylu 1,3,4,5-tetrahydro-2H_ 1,5
• the same operation was performed using 4,5-tetrahydro 2H-1,5-benzodiazepine. Then, the operation was performed according to Step 3 of Example 10 and then to Step 4 of Example 10 to give the title.
• the compound was obtained.
• Example 15 In Step 1 of 5, the same operation was performed using N-tert-butyl-2-iodoacetamide instead of 2-bromo-N-methyl-N-phenylacetamide, and The title compound was obtained by operating according to Step 2 of 15.
• Step 3 of Example 15 1- (N-phenyl-N-methacrylic acid rubamoyl methyl) 1-2-oxo-13-amino-1-5-phenyl-1-1,3,4,5-tetrahydro2 1- (N-tert-butylcarbamoylmethicide) 1- (N-tert-butylcarbamoylmethicide) 1- (N-tert-butylcarbamoylmethicide) 1- (2-oxo-2-3-amino-5-phenyl-1,3-, 4,5-tetrahydro-2H- 1,5 The same operation was performed using benzodiazepine to obtain the title compound.
• Step 3 of Example 15 5 the following procedure was carried out in step 3 of Example 1 ( ⁇ -phenyl- ⁇ -meth-l-butane-rubumoy-methyl) ⁇ ⁇ ⁇ 2-oxo-1 ⁇ 3-amino-5-phenyl-1-1,3,4,5-— 1- (2,2-dietinoethyl) 1-2-oxo-1 3-amino-5-benzoyl 1,1,3,4,5-tetrahydro 2 instead of 1,5-benzodiazepine The same operation was performed using 1,5-benzodiazepine to obtain the title compound.
• Example 1 (2-toluoylmethyl) —2-oxo-1-3-amino-5-phenyl-1,3-, 4-5-tetrahydro 2H—1, obtained in Step 2 of 8
• 5-benzodiazepine 90 mg
• tetrahydrofuran 10 ⁇
• ⁇ -trilysocyanate 34 mg
• Step 3 of Example 15 1- (N-phenyl-N-methylcarbamoyl 1 2—Oki2 3—Amino 1—5—Fe—2,3,4,5—Tetrahydro 1—2 H—1,5—Benzodiazepine instead of 1— (N—Fe2ru N—Met (Lucarbamoylmethyl) 1-2-oxo-3-amino-5-methyl-1,3,4,5-tetrahydro 2H-1,5 The same procedure was carried out using benzodiazepine to give the title compound.
• step 1 of Example 1 2-oxo-3-tert-butoxycarbonylamino 1,3,4,5-tetrahydro 2H-1, 5-benzodiazepine was replaced with 2-oxo-13-benzyl
• the same procedure was carried out using oxycarboamino-1,3-, 4,5-tetrahydro 2H-5-benzodiazepine to obtain the title compound.
• Example 3 In Step 3 of 8, instead of 1-phenyl-2-oxo-3-benzyloxycarbonylamino-5-isobutyryl-1,3,4,5-tetrahydro 2H—1,5-benzodiazepine 1 1 (2,2-Dietokinechi) — 2 —oxo-1 3 —benzyloxycarbonylamino 1 —5-bivaloylu 1,3,4,5—tetrahydro 2H—1,5-benzodiazepine The title compound was obtained.

Priority Applications (8)

Applications Claiming Priority (4)

Publications (1)

Family

ID=26483957

Family Applications (1)

Country Status (12)

Cited By (9)

Families Citing this family (35)

Citations (3)

Family Cites Families (9)

• 1997
  • 1997-12-10 CN CN97181599A patent/CN1130351C/zh not_active Expired - Lifetime
  • 1997-12-10 EP EP97947872A patent/EP0945445B9/en not_active Expired - Lifetime
  • 1997-12-10 WO PCT/JP1997/004534 patent/WO1998025911A1/ja active IP Right Grant
  • 1997-12-10 CA CA002274669A patent/CA2274669C/en not_active Expired - Lifetime
  • 1997-12-10 US US09/319,249 patent/US6239131B1/en not_active Expired - Lifetime
  • 1997-12-10 ES ES97947872T patent/ES2206754T3/es not_active Expired - Lifetime
  • 1997-12-10 JP JP52649598A patent/JP3999819B2/ja not_active Expired - Fee Related
  • 1997-12-10 KR KR1019997005193A patent/KR100531235B1/ko not_active IP Right Cessation
  • 1997-12-10 DE DE69724644A patent/DE69724644D1/de not_active Expired - Lifetime
  • 1997-12-10 AU AU54100/98A patent/AU721081B2/en not_active Expired
  • 1997-12-10 AT AT97947872T patent/ATE248823T1/de active
  • 1997-12-10 DE DE69724644T patent/DE69724644T4/de not_active Expired - Lifetime
  • 1997-12-10 PT PT97947872T patent/PT945445E/pt unknown

Patent Citations (3)

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events